Leonard Saltz, MD: The unsustainable cost of cancer drugs

Interviewed by Steven Greer, MD

Leonard Saltz, MD, of Memorial Sloan-Kettering Cancer Center, discusses how the targeted cancer drugs developed within the last 5 years (Avastin, Tarceva, Sutent, Nexavar, etc) are escalating the total cost burden per cancer patient to unsustainable levels.


No Comments

No comments yet.

RSS feed for comments on this post. TrackBack URI

Leave a comment

WordPress Themes